Low‐dose UVA1 phototherapy for scleroderma: what benefit can we expect?

摘要: Background  The first reports of the application ultravioletA1 (UVA1) phototherapy for scleroderma go back only to 1995, but since then, several studies have proven its effectiveness in this disease. Objectives  To evaluate low-dose (35 J/cm2) UVA1 patients with scleroderma, trying define subgroups that benefit most from treatment. Methods  Retrospective analysis diagnosed clinical and/or histological undergoing between 2003 and 2010. Results  We studied 21 (20 women one man) aged 10–75 years (mean 50). Eighteen morphea performed a total 29 treatments, an average 33 sessions per treatment patient, mean dose 31 J/cm2 session cumulative 1662 J/cm2 (310–4270). three systemic underwent five 26 29.5 J/cm2 1160 J/cm2 (660–1695). Using modified Rodnan skin score, group morphea, marked improvement was found 77.8% moderate 11.1% patients. In group, patient complete remission sclerosis is emphasized. Conclusions  Our experience allows us conclude well tolerated option, excellent results mainly morphea. This valuable contribution these patients, given limited therapeutic options available.